feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New Pill Beats Statins for Cholesterol

New Pill Beats Statins for Cholesterol

5 Feb

•

Summary

  • New pill drastically cuts LDL cholesterol in high-risk patients.
  • Enlicitide shows promise as an easier alternative to injections.
  • Study data is being submitted for FDA approval.
New Pill Beats Statins for Cholesterol

An experimental pill named enlicitide has demonstrated a remarkable ability to reduce high LDL cholesterol levels in patients at elevated risk for heart attacks, even when they are already undergoing statin therapy. This novel medication aids the body in clearing cholesterol through a mechanism distinct from statins, offering a potentially more convenient oral option compared to existing injectable treatments.

In a large-scale study involving over 2,900 high-risk patients, those who took a daily enlicitide pill alongside their standard treatment experienced up to a 60% decrease in LDL cholesterol within six months. This significant reduction was sustained over a year with no adverse safety findings compared to the placebo group.

Statins are foundational in cholesterol management by limiting liver production, but many patients require additional intervention. While powerful PCSK9 inhibitor injections exist, their uptake is limited due to administration complexity and cost. Enlicitide aims to bridge this gap.

Merck has sponsored the research and is pursuing expedited FDA review for enlicitide. Although the pill's ability to lower cholesterol is compelling, further studies are underway to confirm if this reduction translates into fewer heart attacks, strokes, and deaths.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Enlicitide is an experimental pill that helps the body clear cholesterol, offering an alternative to statins and injectable medications for lowering LDL cholesterol.
In a study, enlicitide reduced LDL cholesterol by up to 60% in high-risk patients over six months, with sustained benefits over a year.
Data from studies is being submitted to the FDA for approval, and Merck is pursuing an ultra-fast review process.

Read more news on

Healthside-arrow
trending

Bitcoin price struggles amid fragility

trending

Buddha relics travel from Vadodara

trending

Mrunal Thakur wedding rumours

trending

Suzlon Energy Q3 results up

trending

Savannah Guthrie pleads for mother

trending

Lizelle Lee in WPL Final

trending

Australia vs Netherlands warm-up

trending

RCB wins WPL match

trending

Bas de Leede admires Pandya

You may also like

Weight Loss Jab's Hidden Danger: Vision Loss Risk

11 hours ago • 3 reads

article image

Novartis Faces Profit Drop Amid Generic Drug Competition

1 day ago • 8 reads

article image

NHS: Common Statin Side Effects Require Immediate Doctor Call

31 Jan • 40 reads

article image

Sun Pharma Eyes $10B Women's Health Buyout

19 Jan • 82 reads

article image

Bayer Pharma Eyes 30% Margin by 2030

14 Jan • 126 reads

article image